Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review

JOURNAL OF HEART AND LUNG TRANSPLANTATION

卷:40

Review

Milks, Michael Wesley¹  Sahay, Sandeep^2,3  Benza, Raymond L.¹  Farber, Harrison W.⁴ 

[1] Ohio State Univ, Coll Med, Div Cardiovasc Med, Columbus, OH 43210 USA

[2] Houston Methodist Hosp, Div Pulm Crit Care & Sleep Med, Houston Methodist Lung Ctr, Houston, TX 77030 USA

[3] Tufts Med Ctr, Weill Cornell Med Coll, Inst Acad Med, Boston, MA 02111 USA

[4] Tufts Med Ctr, Pulm Crit Care & Sleep Med, Boston, MA 02111 USA

关键词: PAH;    telemedicine;    risk assessment;    COVID-19;    PRO;    quality of life;   

DOI  :  10.1016/j.healun.2020.12.005

来源: Elsevier

【 摘 要 】

Patients affected by pulmonary arterial hypertension (PAH) benefit from intensive, continuous clinical monitoring to guide escalation of treatments that carry the potential to improve survival and quality of life. During the coronavirus disease 2019 pandemic, the need for physical distancing has fueled the expeditious expansion of various telehealth modalities, which may apply in a unique manner to individuals with PAH. Performance of objective risk assessments in patients with PAH remotely via telemedical visits and other telehealth mechanisms is unprecedented and not yet rigorously validated. The uniquely high risk for rapid deterioration in patients with PAH demands a high degree of sensitivity to detect changes in functional assessments. In this review, several telehealth modalities for potential utilization in risk assessment and treatment titration in patients with PAH are explored, yet additional study is needed for their validation with the pre-pandemic care paradigm. (C) 2020 International Society for Heart and Lung Transplantation. All rights reserved.

【 授权许可】

Free